Coherus BioSciences Inc
$ 1.88
4.44%
15 Apr - close price
- Market Cap 256,312,000 USD
- Current Price $ 1.88
- High / Low $ 1.88 / 1.76
- Stock P/E N/A
- Book Value 0.50
- EPS -1.56
- Next Earning Report 2026-05-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.31 %
- ROE 0.33 %
- 52 Week High 2.62
- 52 Week Low 0.71
About
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilars and immuno-oncology market primarily in the United States. The company is headquartered in Redwood City, California.
Analyst Target Price
$6.75
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-17 | 2025-11-06 | 2025-08-07 | 2025-05-07 | 2025-03-11 | 2024-11-06 | 2024-08-08 | 2024-05-09 | 2024-03-13 | 2023-11-06 | 2023-08-02 | 2023-05-08 |
| Reported EPS | -0.34 | -0.33 | -0.39 | -0.35 | -0.28 | -0.01 | -0.14 | -0.32 | -0.62 | -0.41 | -0.38 | -0.75 |
| Estimated EPS | -0.3382 | -0.32 | -0.26 | -0.1252 | -0.1305 | -0.12 | -0.29 | -0.24 | -0.12 | -0.27 | -0.48 | -0.57 |
| Surprise | -0.0018 | -0.01 | -0.13 | -0.2248 | -0.1495 | 0.11 | 0.15 | -0.08 | -0.5 | -0.14 | 0.1 | -0.18 |
| Surprise Percentage | -0.5322% | -3.125% | -50% | -179.5527% | -114.5594% | 91.6667% | 51.7241% | -33.3333% | -416.6667% | -51.8519% | 20.8333% | -31.5789% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-11 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.29 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CHRS
2026-04-09 23:39:52
Coherus Oncology (CHRS) has filed a preliminary proxy statement for its 2026 Annual Meeting, proposing a one-time repricing of 9.54 million employee and consultant stock options and a 7.7 million share increase to its 2014 Equity Incentive Award Plan. The option repricing aims to restore incentive by resetting exercise prices to the closing price on the meeting date, with an extension of terms, while the share increase is crucial for talent attraction and retention in its transition to an oncology company. The Board recommends a "FOR" vote on all proposals, asserting they are in the best interest of the company and stockholders.
2026-04-07 08:10:56
Coherus Oncology, Inc. (NASDAQ:CHRS) has received an average "Hold" recommendation from five research firms, with analysts providing one sell, one hold, and three buy ratings. The average 1-year target price for the stock is $5.5125. Major institutional investors and hedge funds hold 72.82% of the company's stock, and Coherus Oncology recently reported Q4 earnings per share of ($0.34), missing analyst expectations.
2026-03-31 07:23:44
Coherus Oncology Inc. (NASDAQ: CHRS) is identified as a top penny stock with potential to triple money, following its Q4 2025 earnings report. The company showed progress with increased LOQTORZI sales and significant debt reduction, signaling a transition towards an oncology-focused business. Management anticipates further growth through revenue, partnerships, and clinical catalysts in 2026 for its immunotherapy pipeline.
2026-03-26 14:10:00
This article analyzes the historical performance of a $1,000 investment in Coherus (CHRS) over 1, 5, and 10 years, detailing significant losses over the longer terms and underperformance against the S&P 500. It also provides an overview of Coherus Oncology, Inc.'s focus on developing and commercializing antibody-based cancer therapies, highlighting its key product LOQTORZI and pipeline candidates like CHS-114 and casdozokitug. The company's strategic emphasis on combination therapies for various solid tumors and its corporate information are also discussed.
2026-03-26 05:40:11
DelveInsight's report highlights significant advancements in the Metastatic Hepatocellular Carcinoma (HCC) pipeline, with over 20 companies and 25+ pipeline drugs in development. Key clinical trial updates include Coherus Oncology Inc.'s Phase 2 trial for SRF388 and AstraZeneca's Phase I/II study for AZD5851. The report details several promising emerging drugs like CS1003, Casdozokitug, TTI-101, and ST316, emphasizing the robust research efforts to address this challenging cancer.
2026-03-19 16:40:04
Coherus BioSciences, Inc. (CHRS) announced a proposed public offering of its common stock. The offering will be underwritten by Jefferies and TD Cowen as joint book-running managers. The company intends to grant the underwriters a 30-day option to purchase additional shares.
